Comprehensive assay for the molecular profiling of cancer by target enrichment from formalin‐fixed paraffin‐embedded specimens

Tumor molecular profiling is becoming a standard of care for patients with cancer, but the optimal platform for cancer sequencing remains undetermined. We established a comprehensive assay, the Todai OncoPanel (TOP), which consists of DNA and RNA hybridization capture‐based next‐generation sequencing panels. A novel method for target enrichment, named the junction capture method, was developed for the RNA panel to accurately and cost‐effectively detect 365 fusion genes as well as aberrantly spliced transcripts. The TOP RNA panel can also measure the expression profiles of an additional 109 genes. The TOP DNA panel was developed to detect single nucleotide variants and insertions/deletions for 464 genes, to calculate tumor mutation burden and microsatellite instability status, and to infer chromosomal copy number. Clinically relevant somatic mutations were identified in 32.2% (59/183) of patients by prospective TOP testing, signifying the clinical utility of TOP for providing personalized medicine to cancer patients.

[1]  H. Aburatani,et al.  Fusion Kinases Identified by Genomic Analyses of Sporadic Microsatellite Instability–High Colorectal Cancers , 2018, Clinical Cancer Research.

[2]  Steven J. M. Jones,et al.  Comprehensive Characterization of Cancer Driver Genes and Mutations , 2018, Cell.

[3]  Li Ding,et al.  Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics , 2018, Cell.

[4]  Steven J. M. Jones,et al.  Pathogenic Germline Variants in 10,389 Adult Cancers. , 2018, Cell.

[5]  K. Cole,et al.  Comprehensive Analysis of Hypermutation in Human Cancer , 2017, Cell.

[6]  E. Clappier,et al.  The MLL recombinome of acute leukemias in 2017 , 2017, Leukemia.

[7]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[8]  J. Pietenpol,et al.  Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue , 2017, BMC Cancer.

[9]  Virunya S Bhat,et al.  Editor's Highlight: Dose-Response Analysis of RNA-Seq Profiles in Archival Formalin-Fixed Paraffin-Embedded Samples. , 2016, Toxicological sciences : an official journal of the Society of Toxicology.

[10]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  Javed Siddiqui,et al.  The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing , 2015, Genome research.

[12]  Mark Rosenzweig,et al.  Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. , 2015, Cancer discovery.

[13]  N. Schultz,et al.  Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. , 2015, Cancer discovery.

[14]  S. Fox,et al.  Applicability of Next Generation Sequencing Technology in Microsatellite Instability Testing , 2015, Genes.

[15]  A. Iafrate,et al.  Anchored multiplex PCR for targeted next-generation sequencing , 2014, Nature Medicine.

[16]  Hiromi Nakamura,et al.  Trans-ancestry mutational landscape of hepatocellular carcinoma genomes , 2014, Nature Genetics.

[17]  Anne-Mette K. Hein,et al.  Next-Generation Sequencing of RNA and DNA Isolated from Paired Fresh-Frozen and Formalin-Fixed Paraffin-Embedded Samples of Human Cancer and Normal Tissue , 2014, PloS one.

[18]  Lei Wang,et al.  FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer , 2014, Clinical Cancer Research.

[19]  Atsushi Tanaka,et al.  Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma , 2014, Nature Genetics.

[20]  Kai Ye,et al.  MSIsensor: microsatellite instability detection using paired tumor-normal sequence data , 2014, Bioinform..

[21]  I. Petersen,et al.  CD74-NRG1 fusions in lung adenocarcinoma. , 2014, Cancer discovery.

[22]  L. Garraway,et al.  Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer , 2013, Nature Medicine.

[23]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[24]  Aviv Regev,et al.  Comprehensive comparative analysis of RNA sequencing methods for degraded or low input samples , 2013, Nature Methods.

[25]  Aviv Regev,et al.  Corrigendum: Comparative analysis of RNA sequencing methods for degraded or low-input samples , 2013, Nature Methods.

[26]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[27]  R. Sciot,et al.  Fusion of the AHRR and NCOA2 genes through a recurrent translocation t(5;8)(p15;q13) in soft tissue angiofibroma results in upregulation of aryl hydrocarbon receptor target genes , 2012, Genes, chromosomes & cancer.

[28]  Yasushi Totoki,et al.  KIF5B-RET fusions in lung adenocarcinoma , 2012, Nature Medicine.

[29]  Yuki Togashi,et al.  RET, ROS1 and ALK fusions in lung cancer , 2012, Nature Medicine.

[30]  Doron Lipson,et al.  Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies , 2012, Nature Medicine.

[31]  Marc Ladanyi,et al.  Advances in sarcoma genomics and new therapeutic targets , 2011, Nature Reviews Cancer.

[32]  S. Nelson,et al.  Improved variant discovery through local re-alignment of short-read next-generation sequencing data using SRMA , 2010, Genome Biology.

[33]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[34]  J. Maguire,et al.  Solution Hybrid Selection with Ultra-long Oligonucleotides for Massively Parallel Targeted Sequencing , 2009, Nature Biotechnology.

[35]  Z. Xuan,et al.  Genome-wide in situ exon capture for selective resequencing , 2007, Nature Genetics.

[36]  David T. Okou,et al.  Microarray-based genomic selection for high-throughput resequencing , 2007, Nature Methods.

[37]  Jay Shendure,et al.  Multiplex amplification of large sets of human exons , 2007, Nature Methods.

[38]  G. Weinstock,et al.  Direct selection of human genomic loci by microarray hybridization , 2007, Nature Methods.

[39]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[40]  Hanlee P. Ji,et al.  Multigene amplification and massively parallel sequencing for cancer mutation discovery , 2007, Proceedings of the National Academy of Sciences.

[41]  M. D. Boer,et al.  The MLL recombinome of acute leukemias , 2006, Leukemia.

[42]  F. Mertens,et al.  Extraskeletal Myxoid Chondrosarcoma with Neuroendocrine Differentiation: A Case Report with Fine-Needle Aspiration Biopsy, Histopathology, Electron Microscopy, and Cytogenetics , 2003, Ultrastructural pathology.

[43]  M. Yoshida,et al.  Molecular characterization of the genomic breakpoint junction in a t(11;22) translocation in Ewing sarcoma , 1999, Genes, chromosomes & cancer.

[44]  J. Goldman,et al.  Characterization of genomic BCR‐ABL breakpoints in chronic myeloid leukaemia by PCR , 1995, British journal of haematology.

[45]  P. Nowell,et al.  Heterogeneity of chromosome 22 breakpoint in Philadelphia-positive (Ph+) acute lymphocytic leukemia. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Donavan T. Cheng,et al.  Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. , 2016, JAMA oncology.